Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: A randomized, double-blind, placebo-controlled trial.

Ansari, Sahar; Sanjari Moghaddam, Hossein; Basti, Fatemeh A; Salehi, Mohammadreza; Akhondzadeh, Shahin

Ansari, Sahar; Sanjari Moghaddam, Hossein; Basti, Fatemeh A; Salehi, Mohammadreza; Akhondzadeh, Shahin.

Afiliação

Ansari S; Psychosomatic Medicine Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sanjari Moghaddam H; Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Basti FA; Islamic Azad University, Tehran Medical Branch, Tehran, Iran.
Salehi M; Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Infectious Diseases Department, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Akhondzadeh S; Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: s.akhond@neda.net.

J Psychosom Res ; 174: 111471, 2023 Nov.

Article em En | MEDLINE | ID: mdl-37660680

Palavras-chave

COVID-19; Celecoxib; Depressive symptoms; Post-COVID-19 depressive symptoms

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_doencas_nao_transmissiveis / 1_doencas_transmissiveis Tipo de estudo: Clinical_trials / Diagnostic_studies Idioma: En Revista: J Psychosom Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Irã

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google